Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors

Next Previous
Search
Trial Profile

A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AIM-001 (Primary) ; Checkpoint kinase inhibitors
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Rectal cancer; Sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms BETA-PRIME
  • Sponsors EpicentRx

    • Most Recent Events

    • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2024 According to EpicentRx media release ,company announced that clinical trial led by Dr. Anthony P. Conley from MDACC and Dr. Lucy B. Kennedy from the Cleveland Clinic.
    • 23 May 2024 According to EpicentRx media release,company announced that The American Society of Clinical Oncology has invited Dr. Anthony P. Conley, an MD Anderson Cancer Center Sarcoma Specialist and Lead PI, to give an oral presentation on the unprecedented clinical activity of AdAPT-001 plus an immune checkpoint inhibitor in the ongoing Phase 2 open-label BETA PRIME clinical trial that has so far enrolled close to 70 patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top